Ipsen, a company focusing on oncology, has made a deal with Sutro Biopharma for their first antibody drug conjugate (ADC), STRO-003. This ADC targets ROR1, a tumor antigen overexpressed in various cancers. Sutro’s technology allows for precise drug conjugation, potentially making STRO-003 a leading ADC. Ipsen paid $92 million upfront for the rights to STRO-003 and will handle clinical development and commercialization. The deal includes additional milestone payments totaling up to $447 million and royalties from sales. Ipsen’s focus on cancer has been lucrative, with recent acquisitions and partnerships expanding their portfolio and revenue.
Source link
Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target
